4.4 Opioids

Applying Domain I.D to opioids

Task I.D.1–4 applied to opioids covers pharmacology (class, potency, receptor action), intoxication and overdose, withdrawal, and physiological, psychological, and social effects. Domain I is 25% of the ADC Examination (ADC Candidate Guide, effective November 2022, checked 2026-09-20). This section is independent ADC study material by OpenExamPrep. OpenExamPrep does not claim IC&RC approval, partnership, or exact equivalence with IC&RC training. Full receptor math also appeared in chapter 3; here the class gets its own depth, including medications for opioid use disorder. A later chapter returns to those medications as recovery pathways.

Northbridge's Dana Ellis meets Andre Cole, age 41, who has been using illicit fentanyl. His pupils are pinpoint at intake. He wants buprenorphine this afternoon after using this morning. His sister asks whether he can get the extended-release naltrexone shot tomorrow so he never has to take an opioid again. A colleague wonders why Andre cannot just pick up methadone at a primary-care office like any other prescription.

Pharmacology: natural, semi-synthetic, synthetic, and potency

Opiates are natural opium-poppy alkaloids. Opioids is the broader term for anything that acts at opioid receptors.

Fentanyl is commonly taught as about 50–100 times as potent as morphine. Tiny milligram errors kill people with lost or no tolerance. Illicit tablets and powders are not labeled. Carfentanil and other analogs can be still more potent; counselors do not need a veterinary dose chart, but they should not treat a fentanyl exposure as leftover oxycodone.

At the mu receptor: heroin, morphine, oxycodone, hydromorphone, fentanyl, and methadone are full agonists. Buprenorphine is a high-affinity partial agonist with a ceiling on respiratory depression relative to full agonists—not a promise that overdose is impossible, especially with benzodiazepines, alcohol, or other depressants. Naloxone is a short-acting antagonist for overdose. Naltrexone is a longer-acting antagonist for planned blockade (oral or extended-release intramuscular).

Intoxication, miosis, overdose, and withdrawal

Intoxication: analgesia, euphoria or nodding, warmth, miosis (pinpoint pupils), constipation, itching, slowed breathing. Overdose is decreased consciousness plus respiratory depression, often with miosis. Miosis is not required to give naloxone when breathing is failing and opioids are plausible. Naloxone's clinical effect often lasts about 30–90 minutes; fentanyl and methadone can outlast that window, so stay and repeat. Naloxone does not reverse alcohol or benzodiazepines.

Opioid withdrawal in otherwise healthy adults is usually not fatal, but it is severe: yawning, piloerection, lacrimation, rhinorrhea, mydriasis (pupils go wide—the opposite of overdose miosis), myalgias, diarrhea, vomiting, hypertension, anxiety, and craving. Onset is earlier after heroin or many fentanyl exposures (often about 8–12 hours) and later after methadone (often 24–36 hours, lasting longer). Lost tolerance after withdrawal is an overdose setup if Andre uses his old dose. Pregnancy makes opioid withdrawal higher risk; do not call it just flu for a pregnant client.

Physiological effects: constipation and bowel obstruction risk, hypogonadism and low libido, dry mouth, immunosuppression, infectious disease from injection (HIV, hepatitis C, endocarditis, abscess), neonatal opioid withdrawal after prenatal exposure, and fatal respiratory depression. Psychological effects: intense craving, depression, anhedonia, and relief-driven use. Social effects: overdose deaths in households, incarceration, stigma, family rupture, job loss, and the housing instability that follows a revived-then-discharged emergency visit.

Methadone, buprenorphine, naltrexone, and the MAT Act

Methadone for opioid use disorder is a full mu agonist with a long, variable half-life. In the United States it is dispensed for OUD through certified opioid treatment programs (OTPs) under 42 CFR Part 8, not as ordinary office-based prescribing the way buprenorphine now can be. (Hospital exceptions for acute care exist; they are not a loophole for Dana to send Andre to a retail pharmacy for take-home methadone bottles.) Methadone can prolong the QTc interval and raise torsades de pointes risk, especially at higher doses or with other QTc-prolonging drugs; medical teams obtain ECGs per protocol. Peak respiratory depression can lag the first doses—another reason OTP induction is structured.

Buprenorphine can be prescribed in office-based settings by practitioners with a standard DEA registration and Schedule III authority, subject to state law. The Mainstreaming Addiction Treatment (MAT) Act, enacted in the Consolidated Appropriations Act, 2023 (signed 29 December 2022), eliminated the federal X-waiver (DATA-2000 waiver), patient caps tied to that waiver, and the extra X-number on prescriptions. A separate MATE Act training attestation applies to many new or renewing DEA registrations; do not confuse that one-time training rule with a surviving X-waiver. Because buprenorphine binds mu receptors tightly as a partial agonist, giving it while a full agonist (heroin, fentanyl, methadone) still occupies receptors can precipitate withdrawal—sudden yawning, vomiting, and gooseflesh. Andre using fentanyl this morning is why Dana does not cheer a same-hour first strip without a medical induction plan (including newer low-dose or overlapping protocols that clinicians, not counselors, choose).

Naltrexone occupies mu receptors and blocks agonists. Starting it too soon also precipitates withdrawal. Typical teaching is an opioid-free window of about 7–10 days after short-acting opioids and often 10–14 days after methadone, sometimes with a naloxone challenge, before oral or extended-release naltrexone. Andre's sister wanting the shot tomorrow after last-night fentanyl is a precipitated-withdrawal plan, not a shortcut to being opioid-free.

Opioid traps

1. Treating fentanyl like low-potency leftover oxycodone.
2. Withholding naloxone because pupils are not pinpoint.
3. Offering office-based methadone as if the MAT Act also opened retail methadone for OUD.
4. Assuming the X-waiver still limits every buprenorphine prescriber in 2026 federal law.
5. Starting buprenorphine or naltrexone on a full-agonist board and calling the crash an allergy.
6. Minimizing withdrawal so Andre leaves, loses tolerance, and dies after the next fentanyl bag.